Advanced Immunotherapy Co., Ltd. announced that it concluded an investment contract to receive a round of equity funding on November 20, 2016. The transaction will include participation from GreenPeptide Co., Ltd. to acquire 67% stake in the company. The transaction will take place through third party capital increase. The board of directors of the investor has approved the transaction. The transaction is expected to close by December 1, 2016.